ADCT Stock Analysis: Buy, Sell, or Hold?
ADCT - ADC Therapeutics SA
$3.75
0.11 (3.02%)
▲
5d:
-4.82%
30d:
-10.29%
90d:
+7.14%
BUY
HIGH Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
ADCT is down 4.0% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 124 OI. Call ratio: 100% View Scanner →
Strength: 7.0/10
Get Alerted When ADCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ADCT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ADCT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ADCT is currently trading at $3.75, which is considered oversold relative to its 30-day fair value range of $3.86 to $4.41.
Technical Outlook: Technically, ADCT is showing sideways momentum. Immediate support is located at $3.56, while resistance sits at $4.13. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.20 (+118.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADCT is showing sideways momentum. Immediate support is located at $3.56, while resistance sits at $4.13. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.20 (+118.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.86 -
$4.41
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 118.7% below Wall St target ($8.20)
Fair Price Analysis
30-Day Fair Range
$3.86 -
$4.41
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.56
Resistance Level
$4.13
Current Trend
Sideways
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.90
Wall Street Target
$8.20
(+118.7%)
Revenue Growth (YoY)
36.4%
Profit Margin
-175.3%
Share & Embed Analysis
Last updated: April 01, 2026 8:18 AM ET
Data refreshes hourly during market hours. Next update: 9:18 AM
Data refreshes hourly during market hours. Next update: 9:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 66 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 BUY |
